PDF下载 ( 607 KB)
《肝硬化门静脉高压症食管、胃底静脉曲张破裂出血诊治专家共识（2025版）》解读
DOI: 10.12449/JCH260310
利益冲突声明：本文不存在任何利益冲突。
作者贡献声明：张兴元、曹学峰负责提供写作思路并修改论文；范钟辰负责查阅文献，撰写文章；张凯旋、张阳负责编辑文章；张兴元负责最终定稿。
Interpretation of expert consensus on diagnosis and treatment of esophagogastric variceal bleeding in cirrhotic portal hypertension （2025 edition）
-
摘要: 肝硬化门静脉高压症是因肝硬化造成门静脉系统压力持续性增高而引发的一组临床综合征，并可引起一系列并发症。其中，食管、胃底静脉曲张破裂出血因发生紧急、病死率高，已成为门静脉高压症最严重的并发症之一。自《肝硬化门静脉高压症食管、胃底静脉曲张破裂出血诊治专家共识（2019版）》发布以来，国内外在该领域的研究已取得显著进展。为制定符合我国国情的专家共识，中华医学会外科学分会相关专家组织并编撰《肝硬化门静脉高压症食管、胃底静脉曲张破裂出血诊治专家共识（2025版）》。本文将解读新版共识的更新要点，探讨新、旧版共识的主要差异，旨在强化临床医生对新版共识的理解，为临床医生在相关工作中提供借鉴和参考。Abstract: Cirrhotic portal hypertension is a clinical syndrome caused by persistently elevated portal venous pressure due to liver cirrhosis and can lead to a series of complications， among which esophagogastric variceal bleeding has become one of the most severe complications due to sudden onset and a high mortality rate. Since the release of Expert consensus on diagnosis and treatment of esophagogastric variceal bleeding in cirrhotic portal hypertension （2019 edition）， significant advances have been achieved in this field in China and globally. In order to formulate an expert consensus aligned with the situation of China， Chinese Society of Surgery， Chinese Medical Association organized and compiled Expert Consensus on diagnosis and treatment of esophagogastric variceal bleeding in cirrhotic portal hypertension （2025 edition）. This article elaborates on the key updates in the new edition and explores the major differences between the old and new editions， in order to enhance the understanding of the new edition among clinicians and provide a reference for clinicians in clinical work.
-
Key words:
- Liver Cirrhosis /
- Hypertension， Portal /
- Esophageal and Gastric Varices /
- Diagnosis /
- Therapeutics /
- Consensus
-
[1] JIA LY, NIE YQ, XIE B, et al. Safe platelet threshold in patients undergoing endoscopic variceal ligation and cyanoacrylate injection due to esophagogastric variceal bleeding: Consensus and challenges[J]. J Clin Hepatol, 2025, 41( 9): 1908- 1912. DOI: 10.12449/JCH250929.贾璐瑶, 聂玉强, 谢飚, 等. 食管胃静脉曲张破裂出血行内镜下曲张静脉套扎术和内镜下组织胶注射术的血小板安全阈值: 共识与挑战[J]. 临床肝胆病杂志, 2025, 41( 9): 1908- 1912. DOI: 10.12449/JCH250929. [2] Chinese Society of Portal Hypertension, Chinese Society of Surgery, Chinese Medical Association. Expert consensus on diagnosis and treatment of esophagogastric variceal bleeding in cirrhotic portal hypertension(2015)[J]. Chin J Pract Surg, 2015, 35( 10): 1086- 1090. DOI: 10.7504/CJPS.ISSN1005-2208.2015.10.16.中华医学会外科学分会门静脉高压症学组. 肝硬化门静脉高压症食管、胃底静脉曲张破裂出血诊治专家共识(2015)[J]. 中国实用外科杂志, 2015, 35( 10): 1086- 1090. DOI: 10.7504/CJPS.ISSN1005-2208.2015.10.16. [3] Chinese Society of Spleen and Portal Hypertension Surgery, Chinese Society of Surgery, Chinese Medical Association. Expert consensus on diagnosis and treatment of esophagogastric variceal bleeding in cirrhotic portal hypertension(2019 edition)[J]. Chin J Surg, 2019, 57( 12): 885- 892. DOI: 10.3760/cma.j.issn.0529-5815.2019.12.002.中华医学会外科学分会脾及门静脉高压外科学组. 肝硬化门静脉高压症食管、胃底静脉曲张破裂出血诊治专家共识(2019版)[J]. 中华外科杂志, 2019, 57( 12): 885- 892. DOI: 10.3760/cma.j.issn.0529-5815.2019.12.002. [4] Chinese Society of Spleen and Portal Hypertension Surgery, Chinese Society of Surgery, Chinese Medical Association. Expert consensus on the diagnosis and treatment of esophageal and gastric variceal rupture bleeding in cirrhotic portal hypertension(2025 edition)[J]. Chin J Dig Surg, 2025, 24( 3): 271- 280. DOI: 10.3760/cma.j.cn115610-20241228-00590.中华医学会外科学分会脾及门静脉高压外科学组. 肝硬化门静脉高压症食管、胃底静脉曲张破裂出血诊治专家共识(2025版)[J]. 中华消化外科杂志, 2025, 24( 3): 271- 280. DOI: 10.3760/cma.j.cn115610-20241228-00590. [5] SEMMLER G, LENS S, MEYER EL, et al. Non-invasive tests for clinically significant portal hypertension after HCV cure[J]. J Hepatol, 2022, 77( 6): 1573- 1585. DOI: 10.1016/j.jhep.2022.08.025. [6] JACHS M, HARTL L, SIMBRUNNER B, et al. Prognostic performance of non-invasive tests for portal hypertension is comparable to that of hepatic venous pressure gradient[J]. J Hepatol, 2024, 80( 5): 744- 752. DOI: 10.1016/j.jhep.2023.12.028. [7] de FRANCHIS R, BOSCH J, GARCIA-TSAO G, et al. Baveno VII- Renewing consensus in portal hypertension[J]. J Hepatol, 2022, 76( 4): 959- 974. DOI: 10.1016/j.jhep.2021.12.022. [8] DAJTI E, RAVAIOLI F, ZYKUS R, et al. Accuracy of spleen stiffness measurement for the diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease: A systematic review and individual patient data meta-analysis[J]. Lancet Gastroenterol Hepatol, 2023, 8( 9): 816- 828. DOI: 10.1016/S2468-1253(23)00150-4. [9] WANG HY, LIANG WH, ZHOU L, et al. Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis[J]. Clin Mol Hepatol, 2025, 31( 3): 866- 880. DOI: 10.3350/cmh.2024.0609. [10] JIANG X, PAN J, XU Q, et al. Diagnostic accuracy of magnetically guided capsule endoscopy with a detachable string for detecting oesophagogastric varices in adults with cirrhosis: Prospective multicentre study[J]. BMJ, 2024, 384: e078581. DOI: 10.1136/bmj-2023-078581. [11] FERRARESE A, BUCCI M, ZANETTO A, et al. Prognostic models in end stage liver disease[J]. Best Pract Res Clin Gastroenterol, 2023, 67: 101866. DOI: 10.1016/j.bpg.2023.101866. [12] KIM WR, MANNALITHARA A, HEIMBACH JK, et al. MELD 3.0: The model for end-stage liver disease updated for the modern era[J]. Gastroenterology, 2021, 161( 6): 1887- 1895. DOI: 10.1053/j.gastro.2021.08.050. [13] KIM RG, LOOMBA R, PROKOP LJ, et al. Statin use and risk of cirrhosis and related complications in patients with chronic liver diseases: A systematic review and meta-analysis[J]. Clin Gastroenterol Hepatol, 2017, 15( 10): 1521- 1530. DOI: 10.1016/j.cgh.2017.04.039. [14] BOSCH J, GRACIA-SANCHO J, ABRALDES JG. Cirrhosis as new indication for statins[J]. Gut, 2020, 69( 5): 953- 962. DOI: 10.1136/gutjnl-2019-318237. [15] SU X, LI WJ, CHEN Z, et al. Meta-analysis of β-blockers for the primary prevention of liver cirrhosis with clinically significant portal hypertension with no or small esophageal varices[J]. Chin J Hepatol, 2022, 30( 11): 1237- 1245. DOI: 10.3760/cma.j.cn501113-20210330-00150.苏鑫, 李文洁, 陈哲, 等. β受体阻滞剂对肝硬化伴临床显著性门静脉高压无或小食管静脉曲张一级预防的Meta分析[J]. 中华肝脏病杂志, 2022, 30( 11): 1237- 1245. DOI: 10.3760/cma.j.cn501113-20210330-00150. [16] FORTEA JI, ALVARADO-TAPIAS E, SIMBRUNNER B, et al. Carvedilol vs. propranolol for the prevention of decompensation and mortality in patients with compensated and decompensated cirrhosis[J]. J Hepatol, 2025, 83( 1): 70- 80. DOI: 10.1016/j.jhep.2024.12.017. [17] VILLANUEVA C, COLOMO A, BOSCH A, et al. Transfusion strategies for acute upper gastrointestinal bleeding[J]. N Engl J Med, 2013, 368( 1): 11- 21. DOI: 10.1056/NEJMoa1211801. [18] XU L, JI F, XU QW, et al. Risk factors for predicting early variceal rebleeding after endoscopic variceal ligation[J]. World J Gastroenterol, 2011, 17( 28): 3347- 3352. DOI: 10.3748/wjg.v17.i28.3347. [19] IBRAHIM M, EL-MIKKAWY A, ABDEL HAMID M, et al. Early application of haemostatic powder added to standard management for oesophagogastric variceal bleeding: A randomised trial[J]. Gut, 2019, 68( 5): 844- 853. DOI: 10.1136/gutjnl-2017-314653. [20] TSAI MH, HUANG HC, PENG YS, et al. Nutrition risk assessment using the modified NUTRIC score in cirrhotic patients with acute gastroesophageal variceal bleeding: Prevalence of high nutrition risk and its independent prognostic value[J]. Nutrients, 2019, 11( 9): 2152. DOI: 10.3390/nu11092152. [21] RENGASAMY S, ALI SM, SISTLA SC, et al. Comparison of 2 days versus 5 days of octreotide infusion along with endoscopic therapy in preventing early rebleed from esophageal varices: A randomized clinical study[J]. Eur J Gastroenterol Hepatol, 2015, 27( 4): 386- 392. DOI: 10.1097/MEG.0000000000000300. [22] WANG XZ, LIU GF, WU JC, et al. Small-diameter transjugular intrahepatic portosystemic shunt versus endoscopic variceal ligation plus propranolol for variceal rebleeding in advanced cirrhosis[J]. Radiology, 2023, 308( 2): e223201. DOI: 10.1148/radiol.223201. [23] SHI Y, GUO H, LI J. TIPS standard procedures and management of surgery-related complications for portal hypertension[J/OL]. Chin J Hepat Surg(Elec Ed), 2025, 14( 3): 372- 378. DOI: 10.3877/cma.j.issn.2095-3232.2025.03.007.石洋, 郭辉, 李坚. 门静脉高压症TIPS操作规范及其手术相关并发症处理[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14( 3): 372- 378. DOI: 10.3877/cma.j.issn.2095-3232.2025.03.007. [24] Chinese Society of Spleen and Portal Hypertension Surgery, Chinese Society of Surgery, Chinese Medical Association. Chinese expert consensus on laparoscopic pericardial devascularization(2022 edition)[J]. Chin J Dig Surg, 2022, 21( 6): 701- 707. DOI: 10.3760/cma.j.cn115610-20220513-00272.中华医学会外科学分会脾及门静脉高压外科学组. 腹腔镜贲门周围血管离断术中国专家共识(2022版)[J]. 中华消化外科杂志, 2022, 21( 6): 701- 707. DOI: 10.3760/cma.j.cn115610-20220513-00272. -
本文二维码
计量
- 文章访问数: 7
- HTML全文浏览量: 2
- PDF下载量: 4
- 被引次数: 0
下载:
